genome. Moreover, neutralizing antibodies may act as opsonins in enhancing phagocytosis of virus particles thereby decreasing viral load.
They may be classified as isolate-specific or cross-neutralizing depending on their ability to neutralize only the autologous virus (a
defined viral strain present in the patient of interest) or heterologous viral strains (strains different from the autologous strain usually 
Impact of host neutralizing responses on control of HCV infection
Anti-HCV antibodies become detectable a few weeks (4 14 weeks) after infection ( , ) ( ). These antibodies target a wide containing HCV-neutralizing antibodies ( ). Despite these evidence, the role of antibodies in HCV clearance has long been questioned as 14 studies reported cases of resolution of HCV infection in the absence of detectable anti-HCV antibodies in standard diagnostic testing ( ) 24
and anti-HCV antibodies present after an initial HCV infection did not prevent re-infection in polytransfused thalassaemic children ( ). 25
Other studies involving either patients with post-transfusion hepatitis C, health care workers or young intravenous drug users, failed to show any clear association between the presence of neutralizing antibodies in the acute phase of infection and viral clearance ( , , ). 20 26 27
Moreover, a recent study showed a higher frequency of neutralizing antibodies during the acute phase of infection in individuals who subsequently developed chronic HCV infection ( ). 28
Overall, these studies suggest that viral clearance can occur in the absence of neutralizing antibodies. However, the heterogeneous patient cohorts, the absence of a well-defined viral inoculum as well as the fact that the viral surrogate ligands used for neutralization assays were derived from different isolates than the virus present in the infected individuals might have precluded the detection of isolate-specific neutralizing antibodies in HCV infected individuals analyzed in these studies.
Most recently, studies using a well defined viral inoculum and autologous surrogate ligands enabled the study of the role of study involving hemodialysis patients with nosocomial acquired HCV infection that were followed over 6 months, demonstrated evidence that viral load appears to correlate with the presence of neutralizing antibodies during the acute phase of infection: emergence of strong neutralizing responses correlated with decrease in viremia and control of HCV replication whereas absent neutralizing response associated with persistent high viremia and failure to control HCV infection ( ). Moreover, in a well characterized single-source outbreak of 30 hepatitis C in young, healthy pregnant women that have been accidentally exposed to HCV and followed-up for over 25 years, viral clearance was associated in the majority of patients with the rapid induction of high-titer and cross-neutralizing antibodies in the acute phase. In contrast, chronic HCV infection was characterized by a complete absence or reduced capacity to neutralize the transmitted virus as well as heterologous viruses in the early phase of infection ( ). However, it is interesting to note that some patients (2 out of HCV-specific T-lymphocytes appear 5 to 9 weeks after infection with the virus ( ) and play an important role in both viral control Fig. 1 and liver injury. CD4 T-cells have major regulatory functions as they help CD8 T-cells to eliminate infected cells and B-cells to immune responses. This is in line with recent studies demonstrating that immune control of other poorly cytopathic viruses, such as lymphocytic choriomeningitis virus or simian immunodeficiency virus/human immunodeficiency virus (HIV) requires a collaboration of both neutralizing antibodies and antiviral cellular responses ( , ).
18 37
Viral escape from host neutralizing responses during HCV infection
In the majority of individuals, the immune system fails to eliminate HCV during the first 6 months after contamination and HCV infection persists. HCV replication, estimated by HCV RNA peripheral blood levels, seems to remain relatively stable in these individuals ( ). Persistent HCV infection is characterized by the induction of HCV-specific antibodies directed against both structural and Fig. 1 non-structural proteins and able to cross-neutralize heterologous viruses or quasispecies that arise in the course of infection ( , , , , 4 26 27 29 , , ). A kinetic study of neutralizing antibody responses against the viral inoculum in a single-source outbreak of HCV infection 36 38 39 showed that isolate-specific as well as cross-neutralizing antibodies emerged during the chronic phase of infection ( ). Paradoxically, 29
these neutralizing antibodies induced during chronic HCV infection are not able to clear the virus. Additionally, an alternative kinetic
study of acute mono-infected patients revealed that high-density lipoprotein (HDL) is a serum factor that impairs the efficiency of the cross-neutralizing antibodies that are present during the acute phase of the disease ( , ). Altogether, these results indicate that HCV has 30 40 evolved mechanism(s) that counteract the impact of the humoral response during both the acute and the chronic phase of the disease.
In line with these data, it has previously been shown that HCV genome complexity was associated with the inability to clear HCV infection and development of chronic disease: whereas resolving hepatitis C was associated with a relative stable pool of viral variants, progression into chronic infection correlated with diversification of the quasispecies population ( ). Taken together, these studies [41] [42] [43] demonstrate that the host neutralizing responses are not able to control the circulating pool of viruses during chronic infection. In contrast to LDL and VLDL, HDL was identified as a serum factor enhancing HCV infectivity ( , ). This effect has been in vitro 40 74 shown to be mediated by apolipoprotein C1 ( , ), that resides in HDL, and by the lipid-transfer properties of SR-BI ( , ), an HDL 26 75 40 74 receptor. Furthermore, the interplay of HCV glycoproteins with HDL and SR-BI is able to mediate protection from cross-neutralizing antibodies present in sera of acute and chronic HCV-infected patients ( , , ). The hypervariable region 1 (HVR1) of the HCV 10 40 76 envelope glycoprotein E2, whose variability has been associated with inability to clear the virus ( ), appeared to play a major role in this 42
process ( ). In fact, infectivity of HCVpp harbouring HVR1-deleted E1E2 glycoproteins was not increased by HDL ( ). Deletion of this 77 40
region in HCVpp that were not efficiently neutralized or cross-neutralized by serum from HCV-infected individuals was able to restore the HCV neutralizing ability of antibodies. Moreover, more antibodies directed against various epitopes of HCV envelope glycoprotein E2
were required to neutralize HCVpp in the presence of HDL whereas this resistance to antibody-mediated neutralization was abolished in as compared to cells grown in distinct compartments separated by a cell-impermeable membrane ( ). Experiments using human 293T 5 9 ). Moreover, as anti-CD81 antibodies partly inhibited cell to cell transfer, direct cell-to-cell transport may in part also be mediated by CD81 ( ). Interestingly, CD81-negative HepG2 human hepatoma cells that are resistant to infection by cell-free HCV were sensitive to 83 HCV infection in this co-culture model system in the presence of virus-neutralizing antibodies suggesting that there are also CD81-independent routes of cell-to-cell transport ( ). CD81-independent cell-to-cell transfer was also demonstrated by the second study 83 showing 
Perspectives for preventive and therapeutic strategies based on neutralizing antibodies
The elucidation of escape mechanisms from adaptive immune responses will be crucial for the understanding of HCV pathogenesis as well as the development of novel preventive and therapeutic strategies for control of HCV infection. Moreover, identifying successful immune responses against HCV as those naturally occurring in individuals spontaneously clearing infection might guide efforts to elicit such immune responses by appropriate vaccination. Data from acute and chronic HCV-infected patients as well as studies in chimpanzees suggest that a vaccine should be able to induce vigorous and multispecific B-and T-cell responses in order to control viral infection and prevent progression to chronicity ( ). 84
In recent years, the study of re-exposure to HCV in intravenous drug users who previously cleared HCV infection suggested that at least partial protection from HCV reinfection might exist in humans ( ). Even if sterilizing immunity against various viral strains might 85 be difficult to achieve, progression into chronic HCV infection and thus development of cirrhosis and hepatocellular carcinoma may be avoided by a preventive or therapeutic vaccine. Moreover, chimpanzee studies have shown that a broad protective immunity against HCV can be induced as chimpanzees that had previously controlled a first infection were able to clear HCV following re-challenge with homologous or heterologous viruses ( ). Vaccination studies in chimpanzees showed that different formulations are able to induce at 86-88 least partial protection of the host against different viral strains and significantly reduced persistent infection ( , ). Interestingly, it 89 90 appears that formulations inducing both cellular and humoral immune responses might be more efficient (reviewed in ( )). In addition, 84 deletion of N-glycosylation sites on HCV envelope glycoproteins leads to stronger and broader cellular and humoral immune response in mouse vaccination studies ( , , ) underscoring the importance of unravelling HCV escape mechanisms to aid vaccine design. 80 81 91 Most recently, human monoclonal cross-neutralizing antibodies directed against conserved epitopes of HCV envelope glycoprotein E1 or E2 were identified ( , ). These antibodies were able to efficiently block infection with heterologous HCV in the HCVpp and 11 -13 92 HCVcc model systems and two of them were able to protect from challenge with heterologous HCV using the human in vivo liver-chimeric Alb-uPA/SCID mouse model ( ). These results further indicate that a prophylactic vaccine against HCV may be 92
achievable ( ). 92
Developing efficient passive immunization in combination with current or future antiviral therapeutics is another important goal to achieve post-exposure prophylaxis for health care workers and to prevent HCV re-infection during liver transplantation. Chronic hepatitis C is currently a leading indication for liver transplantation. Unfortunately, liver transplantation in HCV infected patients is invariably followed by re-infection of the graft. In addition, recurrent hepatitis C in transplant patients is challenging to treat. The fact that cases of HCV infection occurred through the administration of immunoglobulin preparations derived from HCV contaminated plasma from which anti-HCV antibodies had been excluded, suggest that passively transferred anti-HCV antibodies may prevent viral infection in humans (14 ) . Mechanisms of viral escape from antibody-mediated neutralization during HCV entry. HCV binding and entry is a multistep process:
following attachment of viral envelope glycoproteins E1 and E2 to host cell surface molecules, HCV is internalized into the host cell via clathrin-mediated endocytosis. Decreasing pH in the endosome leads to fusion between viral and endosomal membranes and to the release of the viral genome into the cytoplasm (adapted from reference ( )). Viral escape from antibody-mediated neutralization has been shown to 96 occur amongst others including ( ) the interference of non-neutralizing antibodies blocking binding of neutralizing antibodies to viral 1 epitopes, ( ) association of HCV with lipoproteins including low density lipoprotein (LDL) and very low density lipoprotein (VLDL) that 2 may mask neutralizing epitopes; ( ) the interplay of HCV with high density lipoprotein (HDL) and SR-BI that is able to mediate protection 3 from neutralizing antibodies; ( ) the shielding of neutralizing epitopes by glycosylation of amino acids of HCV envelope glycoproteins; and ( 4 ) direct cell-to-cell transfer of the virus. HS -heparan sulfate, LDLR -LDL receptor, SR-BI -scavenger receptor class B type I, CLDN1 -5 claudin-1, X not yet identified host factor(s) for HCV binding and entry.
